Back to search results

Observational Study of Optrell™ Mapping Catheter for Ventricular Arrhythmias

This study is looking at how well a special tool, the Optrell™ mapping catheter with TRUEref technology, works during a procedure called ablation for people with ventricular arrhythmias (irregular heartbeats) that come from the papillary muscles. Researchers believe this catheter can map the heart more quickly and accurately. The study will check if the procedure successfully stops these irregular heartbeats right away and again after three months. You may be able to join if you are between 18 and 75 years old and can give your consent. The study aims to include 20 participants, but its current status is unclear.

Study design
This is an observational study, meaning researchers will watch and record what happens during the ablation procedure using the Optrell™ mapping catheter. It plans to include 20 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3 months after the procedure to check for success in eliminating premature ventricular contractions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07541092

The Comparative Advantage of the Optrell Mapping Catheter in Ventricular Arrhythmias From the Papillary Muscles

Recruiting
Not specifiedAges 18–75Observational
Northwell Health
~20 participants
Updated 2026-04-21 on ClinicalTrials.gov
What's tested:Ablation using Optrell™ mapping catheter

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate acute success in eliminating premature ventricular contractions
Measured over During procedure
+1 more outcome measured

Conditions

Ventricular Arrythmia

Explore related trials

Ventricular Arrhythmia

NCT07541092

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Long Island Jewish Medical Center

    New Hyde Park, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Haisam Ismail, MD · PRINCIPAL_INVESTIGATOR · Northwell Health

Who to contact

Salome Elia Reddy
[email protected]
516-600-1459
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements
Patient is not cognitively impaired, pregnant, prisoner, employed by Northwell, uninsured, or a student
Age 18-75 years old with the ability to consent for the procedure
Patient is consented within the enrollment window of the therapy received, as applicable
Patients with frequent (\>10%) or symptomatic PVCs with ECG morphology consistent with papillary muscle origin.
Papillary muscle PVCs in setting of cardiomyopathy.
Patients prescribed by their treating physician to undergo the procedure with the Optrell™ mapping catheter as part of routine clinical care.
Patient demonstrates proficiency in the English language; reading, writing, and conversational

Exclusion

Patient who is, or is expected to be, inaccessible for follow-up
Participation is excluded by local law
Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the study results
Unable to consent
PVC from site other than papillary muscle
Acute coronary syndrome
Congestive heart failure in acute decompensation
Rapid atrial fibrillation
Requiring ventricular pacing

What this trial measures

  • Evaluate acute success in eliminating premature ventricular contractionsDuring procedure
  • Evaluate success at 3 months follow up in eliminating premature ventricular contractionsAt 3 months follow post-procedure